Ehrlich laid the foundation for the modern chemotherapy of syphilis in 1907 with the synthesis of arsphenamine. His original idea of effecting a total sterilization of the body tissues infected with the Tr. pallidum by the intravenous injection of one or a few doses of this drug in massive amounts was, unfortunately, soon shown to be impracticable because of the toxic reactions obtained. In favor of these massive spirocheticidal doses was adopted the present so-called alternating block therapy method in which divided doses are spread over a year or even years.
Ehrlich laid the foundation for the modern chemotherapy of syphilis in 1907 with the synthesis of arsphenamine. His original idea of effecting a total sterilization of the body tissues infected with the Tr. pallidum by the intravenous injection of one or a few doses of this drug in massive amounts was, unfortunately, soon shown to be impracticable because of the toxic reactions obtained. In favor of these massive spirocheticidal doses was adopted the present so-called alternating block therapy method in which divided doses are spread over a year or even years.
It is obvious that this method, spread over a year or years, presents serious disadvantages, chief among which is the fact that probably only 16 per cent or less of the patients treated by this procedure receive adequate therapy as defined by the United States Public Health Service.5 12 Indeed, Russell12 has estimated that in the United States as a whole, 95 per cent of patients with early syphilis received inadequate treatment.
The desirability of adequate treatment and the dangers of inadequate treatment have been stressed by the Cooperative Clinical Group and ably presented by Moore.9 Moreover, Paget's recent presentation10 of the results attained in a group of early syphilitics treated with the conventional form of therapy clearly demonstrates that irregular or intermittent treatment leads to no better results than are obtained with no treatment at all. Indeed, he goes so far as to suggest that if continuous treatment cannot be given, "no treatment is the desideratum."
It is apparent, therefore, that a method which would greatly shorten the duration of treatment and at the same time render noninfectious and cure a large proportion of cases of early syphilis would be of tremendous advantage not only to the infected cases but to public health as well.
The possible answer to this problem is the development, nine years ago, of the continuous-drip method of administering massive doses of the arsenicals by Hyman and his associates Chargin and Leifer in the clinics of the Mount Sinai Hospital. These workers attempted the slow intravenous injection by continuous drip of 4 grams of Neoarsphenamine over a period of 5 days, reporting in 1935 upon a series of 25 cases2' 6 and in 1939 upon an additional 86 cases. 7 The clinical results were good. There was a rapid healing of primary and secondary lesions; dark-field examinations were invariably negative within 48 hours; and it was found that 86 per cent of the cases exhibited complete sero-reversal, usually within 10 to 16 weeks. Two patients became reinfected, 2 suffered a cutaneous relapse, and 2 patients a serological relapse.
However, in view of one fatality due to hemorrhagic encephalitis and to the relatively high incidence of serious reactions, particularly cerebral symptoms, peripheral neuritis, jaundice, and exfoliative dermatitis, the use of Neoarsphenamine was abandoned in favor of Mapharsen (arsenoxide), a much less toxic but nevertheless therapeutically potent drug. Recent reports by Hyman and his group' 8 demonstrate a significantly lower toxicity with this drug. Cerebral symptoms such as convulsions, disorientation, or hemorrhagic encephalitis, though reduced in frequency and not associated with fatality, were still present and offer, perhaps, the greatest drawback to the use of massive arsenotherapy. There were, however, no fatalities in a group of 275 patients treated with Mapharsen. Therapeutic results, as judged by a one-to-two-year follow-up, were satisfactory.
Since January of 1940 this method of massive arsenotherapy by the continuous intravenous drip, and employing Mapharsen as outlined below, has been in use at the New Haven Hospital for the treatment of primary and secondary syphilis. In this report are presented data concerning the procedure, toxicology, clinical observatioIls, and therapeutic results already obtained with this modern form of therapy in early syphilis. Subsequent reports in this series are concerned with the electrocardiographic changes4 and the complicating factor of pregnancy associated with or following therapy.15
Material and Technic
In this study 33 patients were given massive arsenotherapy. Only patients in good physical condition were chosen for this study and all were suffering from early syphilis. Three of these patients (Cases 8, 12, and 13-R. R., M. F., and J. M.) received a second course of therapy at 51, 40, and 19 weeks, respectively, following the first "treatment course." The indications for re-treatment were in order, serological relapse, serological fastness, and reinfection from a known source with the production of a penile chancre.
Other pertinent data are listed in Table 1 , where it can be seen that approximately half of the patients were male and half were female, with approximately the same proportion of white and black races. Twelve of the 33 patients exhibited a primary lesion; 22 had, at the time of treatment or shortly before, manifestations of secondary syphilis. The remaining 2 patients were numbered among those who received re-treatment, in one instance due to a serological relapse, in the other to serological fastness. The age distribution was that ordinarily seen in early syphilis, the majority of patients falling into the early adult group of 20 to 30 years of age.
No additional treatment prior to massive arsenotherapy was administered except for that noted in Table 2 . Eight patients received one or two doses of bismuth subsalicylate in oil intramuscu- of Mapharsen, as previously described by the Mount Sinai group,1 8 have been strictly adhered to, the only minor modification being in regard to the type of intravenous set-up employed. As illustrated in Fig. 1 The method calls for excellent venepuncture technic. It is important that the needle (20 gauge, 1 >2" long, short bevel point) be buried to the hilt and securely anchored as illustrated in Fig. 2 , so that the patient may move his arm at will without dislodging the needle. Another important factor is the insertion of the needle in the veins of the lower half of the forearm; again, so that the free movement of the arm may be obtained. Each arm is used on alternate days.
Patients received the routine hospital diet, which in most instances was well taken except during the first day when the majority vomited. For the greatest efficiency, it was found desirable to have a special nurse assigned to one or more patients receiving the drip in order to refill the gravity burette, regulate the rate of flow of the Mapharsen solution, and to offer general nursing care. In general, little, and at times no, discomfort was suffered by the patient after the first day of the drip when the Herxheimer reaction ordinarily occurs.
On admission, the patient underwent the following laboratory examinations: blood count including differential and platelet count, complete urine examination, chest x-ray, electrocardiogram, nonprotein nitrogen of the blood, and, in the first half of the series, a liver function test and a phenolsulfonphthalein kidney-excretion test. Since no abnormalities in the two latter tests could be detected at the end of therapy, their routine performance was discontinued. The blood count and urine examinations were repeated during and after the course of therapy, and in most instances the non-protein nitrogen of the blood was checked following the full course of therapy. The platelet count was checked one hour after beginning therapy.7 Details concerning the conduct of the electrocardiographic examinations are reported in a subsequent paper. 4 In practically all cases, lumbar puncture was performed either before or immediately after continuous-drip therapy and, whenever possible, repeat examination of the cerebrospinal fluid with cell count, Pandy, colloidal gold, and Wassermann reaction was carried out from the 3rd to the 6th month and at the end of the first year.
Dark-field examination of material from the primary lesion and in some cases from secondary lesions was done. The standard Kahn test and a modification of the Kolmer complement fixation (qualitative) reaction, hereafter termed the Wassermann test, were employed as the methods of serological study.
Follow-up examinations with clinical and serological checks were performed in the Out-patient Syphilis Clinic of the New Haven Hospital. Toxicology Primary fever. The toxicological data are summarized in Table 3 . A primary fever of IO1.0°o r higher was seen in 14 (39 per cent) of the 36 "treatment courses" administered. Except for 5 patients in this group the temperature did not rise over 103.00 F. This fever ordinarily consisted of a brisk rise in temperature within from 6 to 10 hours after the treatment had been started on the first day and was sometimes accompanied by a chill. The elevation may continue for from 2 to 4 hours and then begins to abate, reaching normal in another 2 to 6 hours despite continued therapy with arsenic. This reaction is, of course, synonymous with the Herxheimer reaction, and discontinuance of therapy is not necessary when it appears. In addition to this severe Although this primary fever of 101.00, or higher, has no serious connotation, we thought it to be of interest to attempt to prevent it by the preliminary injection of a bismuth compound or an arsenical. A glance at the material in Tables 2 and 4 suggests that there is no dear-cut evidence that bismuth is of any aid in preventing the Herxheimer reaction, at least, if the bismuth is given within 5 days of starting therapy. On the other hand, it is clearly evident that in all 5 cases receiving an arsenical prior to massive arsenotherapy, primary fever of 101.00 F., or higher, was not seen in a single instance even though as little as 0.02 gm. of Mapharsen was given 3 days prior to the course of therapy. It is only fair to point out, however, that in this particular case, as severe a Herxheimer reaction as any we have ever seen developed 8 hours after the single 0.02 gm. injection of Mapharsen, with the fever reaching 103.20 F.
Our experience has been similar in other cases of early syphilis receiving the first single dose of an arsenical while under hospital observation. It is clear, therefore, that the Herxheimer reaction is not peculiar to massive arsenotherapy, but can be found with other forms of therapy if the patient is observed.
Secondary fever. Secondary fever of 101.00 or higher was found in 10 (28 per cent) of the cases, and in all but one instance was less than 103.00 F. It usually lasted one or two days, but twice it lasted for 3 days and once for 4 days. This fever appeared between the 3rd and the 6th day, most often on the 5th day. In an additional 10 cases (28 per cent) a low-grade fever of less than 101 .00 F. was seen, beginning on the 4th, 5th, or 6th day and lasting one or two days.
Toxicoderma. The secondary fever described above may appear with a toxicoderma or the toxicoderma may appear without a febrile reaction. In 7 cases such a toxicoderma was seen at the end of therapy. In all but one instance it was associated with fever. Although ordinarily of a maculo-papular type, rashes of erythematous, macular, or urticarial varieties were seen. These rashes were of an evanescent character, disappearing within 24 to 48 hours. No eruption of an exfoliative nature was observed. It may be of interest to comment upon the fact that while Case 8 (R. R.) developed a maculo-papular toxicoderma on the first course of therapy, no eruption and, indeed, no reaction of any type was observed when she was given a second treatment course of massive arsenotherapy because of a serological relapse.
Jaundice. Although liver function (bromsulphalein excretion) tests were carried out before and after therapy on approximately half of the patients, and the icteric index was performed throughout therapy in a few instances, no evidence of damage to the liver was found in this particular group. In a case (35-A. Fr.) apart from this group, however, jaundice developed on the 4th day and because of the complicating factors the following history is related:
The patient, a 20-year-old negress, was admitted with a generalized secondary syphilitic eruption, dark-field positive. She received an injection of 0.06 gm. of Mapharsen intravenously and was discharged the following day, to be followed at frequent intervals with electrocardiograms. It may be noted that she developed a Herxheimer reaction 3 hours after injection, with malaise, vomiting, and fever of 103.0°F. Fourteen days after the initial treatment she was re-admitted for massive arsenotherapy. On routine examination a temperature of 103.20 F. was found with a normal leukocyte count of 8,200 per cu. mm. Despite this fever there were no complaints and since it appeared likely that this fever was that remaining from an "erythema of the 9th day,"1' treatment by means of the constant drip was started on the following morning, a procedure which appears in retrospect to have been unwise. The temperature gradually declined, reaching practically normal by the 5th day of therapy. Vomiting was troublesome throughout the course of therapy. On the night of the 4th day of therapy, there was a suggestive icteric tint to the sclerae. On the following morning, the 5th and final day of therapy, jaundice of the sclerae was definite and the icteric index was 50. There was no bile or urobilin in the urine. Treatment for the day was continued, the patient thus receiving a full course of arsenical therapy. Two days later, the icteric index had dropped to 40. There was a questionably faint positive reaction for bile in the urine, and the non-protein nitrogen of the blood was 30 mg. per cent. Increase in liver dulness suggested that there had been a slight enlargement of the liver. The patient was discharged the following day. On the first follow-up visit, a week after therapy, there was no clinical evidence of jaundice. The liver was not enlarged and the icteric index had dropped to 15. However, the hemoglobin which had ranged between 67 and 78 per cent (15.4 gm. = 100 per cent) up to the time of discharge from the hospital, now had fallen to 55 per cent with a red cell count of 2,500,000 per cu. mm. There was marked weakness, presumably due to the anemia. Ferrous sulfate was administered, and a week later blood examination revealed that there had been a rise to a red cell count of 3,100,000 and the hemoglobin was 62 per cent. The icteric index was 10. However, despite a definite improvement in her fatigue, she complained of numbness and tingling of the right leg and on examination there was found a hypesthesia on the right. Another week later, 3 weeks after therapy, the blood count had risen to 3,900,000 and the hemoglobin was 75 per cent. She now complained bitterly of pain in both legs, especially severe when walking. There was a hypesthesia of both lower extremities up to the knees with patchy areas of hyperesthesia in this region. Thiamine chloride, 50 mg., was given subcutaneously and 15 mg. daily by mouth was prescribed. A week later, the pain was still severe and because of weakness of the extensors of the right hand with hypesthesia, together with weakness which had developed in the extensors of the right foot, she was admitted to the hospital for observation. This is the patient's present status.
It is evident that there are many complications in this case. This patient developed jaundice (and presumably toxic hepatitis) during therapy, this clearing without incident. Shortly after hospital discharge, a severe anemia developed, this also clearing without incident. Three weeks after therapy a peripheral neuritis developed, at first sensory only, then involving the motor fibers to a minor degree.
Peripheral neuritis. Peripheral neuritis, as evidenced by paresthesias in the lower extremities such as numbness and tingling, was found in 18 (50 per cent) of the cases, usually at about the 2nd or 3rd week following therapy. In only 5 cases (14 per cent) was hypesthesia present and except for the one case described above (35-A. Fr.) was minimal, only a stocking hypesthesia of the feet being usually observed. Indeed, the neuritis was ordinarily so mild that only careful questioning elicited any complaints. The paresthesias lasted only for a day or two, the hypesthesias for about a week. All cleared without residual signs or symptoms. Hyman and his associates' have found that the use of vitamin B1 is valueless in this condition, either as a prophylactic or therapeutic agent, when associated with arsenotherapy.
No evidence of motor involvement was made out except for the one case (35-A. Fr.) described above. It would appear reasonable to conclude that this motor neuritis was due to the toxic effects of arsenic. If this is correct, such a reaction would be unusual, since it has not been described in reports from the Mount Sinai Clinic in which Mapharsen was employed. It may be possible that the toxic hepatitis prevented the satisfactory excretion of arsenic to some degree, thus causing the blood concentration of arsenic to rise to dangerously high levels. Nausea and vomiting. Vomiting occurred at least one or more times during therapy in 91 per cent of the patients and in two instances the vomiting was so severe as to be recorded as occurring 50 or more times during the "treatment course." Full details are given in Table 5 , from which it appears that vomiting is decidedly more severe in the female. If our data are analyzed according to the number of days on which the patients vomit (Table 6) , a similar discrepancy between male and female is again evident. The majority of patients vomit for less than three days, and in most instances the vomiting is most severe on the first day of therapy.
Nausea and vomiting seen with massive arsenotherapy are not of serious import, though at times they may be extremely troublesome. We have not found any particular sedative that will control the disturbance. Facilities for electrolyte study were not available, but we rather suspect that electrolyte changes of an extensive nature do not occur, since in three of the cases under study and in which chloride determinations were carried out on the blood serum by one of us at the end of therapy, the chloride values in m.eq. were 89.0, 95.0, and 99.5, the three patients vomiting 53, 19, and 12 times, respectively, during the course of therapy.
Local thrombophlebitis. Pain of a cramp-like nature in the arm and forearm of the extremity being used for injection was seen in practically every case, though in most instances the pain was slight. A moderately severe local thrombophlebitis of the veins of the forearm was seen in 8 (22 per cent) cases, usually on the 4th or 5th day of therapy. In one instance this reaction was severe with marked pain, shaking chills, and a temperature of 104.0 to 105.00 for three days beginning on the 5th day of therapy. Recovery was without incident.
In all instances of thrombosis, the vein re-canalized and could be used for venepunctures within a month or two after treatment.
Leukopenia. A leukocyte count falling to less than 5,000 was seen in two cases at the end of therapy or shortly thereafter. In neither case was there a neutropenia and in both instances the leukocytes returned to a normal level within 48 hours.
Late secondary anemia. In 23 patients the red cell count and the hemoglobin concentration in the blood were observed during the first month of the follow-up period. It was found that in 11 (48 per cent) of this group there was evidence of the development of a secondary type of anemia in which the red cell count had dropped by from 700,000 to 800,000 or more and the hemoglobin concentration by 15 per cent or more. It is only fair to point out that except for three cases (I1-B. B., 3-I. R., and 35-A. Fr.) in which the initial hemoglobin concentration was in the neighborhood of 65 to 75 per cent and in which, with the drop, readings of 55 to 60 per cent were obtained, the anemia was not clinically significant. In these particular instances, marked pallor and fatigue were evident. It may be significant that all three were negresses.
The anemia usually reached its peak by the first or second week following therapy. It is difficult to evaluate the effect of iron therapy in these cases, though it would be our general clinical impression that regeneration of hemoglobin was not materially affected by ferrous sulfate therapy, at least in the patients with a milder form of anemia.
Electrocardiographic changes. Serial electrocardiograms obtained before, during, and after massive arsenotherapy revealed significant abnormalities of the T waves that developed in most of the cases studied during the course of the treatment. 13 The electrocardiographic changes appeared to represent toxic arsenic effects of transient and benign nature, the abnormalities disappearing during the followup period. A detailed presentation of the electrocardiographic studies appears in a subsequent paper of this series. It is obvious then, from this figure, that both the Kahn and Wassermann reactions were positive before the S-day therapy in all but one case. In this specific instance (No. 19-0. P.), the Kahn only was positive before therapy although the Wassermann reaction also became positive during therapy.
In this group of 33 patients with 36 "treatment courses," 19 patients have had a complete sero-reversal, the remainder of the group, with the exception of two cases, having been followed for less than six months after therapy. The rate at which these 19 patients attained sero-negativity is illustrated in Fig. 4 and, in general, the trend toward this status is similar to that described by Elliott et al.3 in a much larger group of patients treated with massive arseno-therapy. Because of the small number of cases involved, no attempt has been made in this graph to analyze separately or to make a comparison of the ultimate status or the rate of return to sero-negativity between the primary and secondary cases of syphilis. It is clear, however, from previous reports on massive arsenotherapy,3' 8 that both the percentage of cases demonstrating sero-reversal and the rate at which they attained sero-negativity are highest in the seronegative primary group, next in the sero-positive group, and lowest in the group with evidences of secondary syphilis.
Four of the 33 patients have been lost for further observation. Of these four patients, two (2-J. Mc. and 10-S. R.) had complete sero-reversals on the 4th and 3rd week, respectively, while in the remaining two cases, the Wassermann reaction had reverted to negative by the 9th week though the Kahn test remained positive at that time, when they were lost for further observation.
Treatment failures. Less than one-half of the group have been followed for a period of 6 months or longer, although sero-reversal has taken place already in a number of patients followed for a shorter period. In that particular group of patients followed for a period of 6 months or longer, and which number 12 (excluding the case with reinfection, Case 13-J. M.), there would appear to be 3 failures, namely, cases 8, 12, and 14, although it is still possible that the last case may have a sero-reversal after 4 or 8 more weeks of observation. Data on these 3 cases are recorded below. CASE 8. R. R., a 24-year-old white female, with subsiding secondary rash of 2 months duration, sero-positive, and an exposure to known syphilitic source 5 months before admission. Sero-reversal occurred 15 weeks after therapy, and she was exposed on many occasions to at least 4 different sources (serologies on sexual partners unknown) for the next 5 months. The Kahn and Wassermann reactions returned to positive 38 weeks after therapy and were interpreted as a serological relapse, since no early lesions of syphilis were discovered during the next 13 weeks of observation. Cerebrospinal fluid negative. Re-treated with massive arsenotherapy (No. 22-R. R.2), no Herxheimer; sero-reversal 10 weeks after second course of therapy. She was seronegative at the last check-up 19 weeks after therapy. CASE 12. M. F., a 28-year-old white female, secondary lesions of 6 weeks duration, sero-positive. Remained sero-positive for 40 weeks, with fluoroscopy and x-ray of the heart negative, complete physical examination negative, cerebrospinal fluid negative on 3 occasions (1, 21, and 36 weeks after therapy) except for a colloidal gold curve of 1244431000. Re-treated with massive arsenotherapy (No. 30-M. F.2), moderately severe Herx-heimer reaction. Cerebrospinal fluid at end of therapy negative (no cells, Pandy and Wassermann negative, protein 21 mg. per cent) except for colloidal gold curve of 4454210000. At 4 weeks after the 2nd course of therapy the serology remains positive. CASE 14. A. P., a 21-year-old white female, secondary lesions of 4 weeks duration, exposure to known syphilitic with penile chancre 6 months before admission, sero-positive. She remains sero-positive 26 weeks after therapy, clinically negative for syphilis. Cerebrospinal fluid not examined since the massive arsenotherapy course was given, at which time it was negative.
Reinfection. One patient (No. 13-J. M.) who had attained sero-negativity 12 weeks after therapy, became sero-positive on the 18th week. It would appear probable that he was reinfected. The following case history is related in support of this view. Retreated cases. No evidence of sensitivity toward arsenic was obtained in the 3 patients who received a second course of treatment, the indications for which are discussed above. Case 8-R. R. vomited 11 times and developed a generalized maculo-papular toxico-derma of 24 hours duration at the end of therapy during the first "treatment course," and during the follow-up period she had mild paresthesias of the lower extremities. With the second course of therapy and follow-up period, no toxic symptoms of any type were observed.
In the case of 12-M. F., there was a mild Herxheimer reaction with minimal vomiting (4 times) during the first day and in the follow-up period, mild paresthesias developed in the feet. During the second "treatment course" there was a moderately severe Herxheimer reaction with vomiting (5 times) during the first day. No evidence of peripheral neuritis has developed up to four weeks of follow-up observation. The third patient, 1 3-J. M., had, as toxic manifestations during the first course of therapy, a secondary fever of 102.40 F. on the 5th day and mild paresthesias of the lower extremities during the follow-up period. With the second course there was a mild Herxheimer reaction, but no evidence of secondary fever and no evidence of peripheral neuritis.
Effect of treatment on Tr. pallidum. In a limited number of cases the data concerning the effect of massive arsenotherapy upon the Tr. pallidum were obtained and are detailed in Table 7 . It is evident that the dark-field examination in 5 cases (3 primary and 2 secondary lesions) was invariably negative 24 hours after the first day's dose was started. Effect of massive arsenotherapy on the cerebrospinal fluid. The status of the cerebrospinal fluid, including cell count, Pandy, colloidal gold curve, and Wassermann reaction, was determined in 4 cases at some time during the 4th to the 15th week after therapy; and in another group of 8 cases similar data were obtained at the 16th to the 35th week. In most instances lumbar puncture was carried out after therapy and served to establish the initial findings. These data are recorded in Tables 8 and 9 .
In Table 8 it is apparent that Cases 13-J. M. and 16-D. F. had cerebrospinal fluid findings of a positive nature, including posi- tive Wassermann reactions and abnormal colloidal gold curves, and in Case 16 a positive Pandy was also present. The follow-up lumbar punctures, in Case 1 3-J. M. on the 5th week and in Case 16 D. F. on the 13th week, were both negative except for an abnormal colloidal gold curve (2455410000) in the latter patient. The significance of this finding, with negative Pandy and Wassermann tests and in the absence of cellular reaction, is difficult to determine. The status of the cerebrospinal fluid in the remaining two patients in Table 8 during the follow-up period, and in all 8 patients in Table 9 in which the lumbar punctures were done at a time between the 16th and 35th weeks, could be adjudged essentially negative.
In an additional 15 patients a similar study on the cerebrospinal fluid, together with determination of total protein, was carried out, although a sufficiient period has not elapsed for follow-up study. Suffice it to say that except for two instances in which the only abnor-mal findings were colloidal gold curves of 1234100000 (Case 21-M. G.) and 4454210000 (Case 30-M. F.2), the cerebrospinal fluid was negative. The values for total proteins ranged from 21 to 45 ng. per cent. Pregnancy as a complication, and its outcome. Observations upon the association of pregnancy with massive arsenotherapy have been afforded in 4 of the cases treated. In two instances (Case 21 -M. G. and Case 33-M. R.), pregnancy was present during the time of treatment, the duration of pregnancy being S weeks in the first case and 14 weeks in the second case. The constant-drip therapy was carried through in both patients without any undue toxic symptoms or sequelae. The fetus, so far as one can tell by maternal inspection, has not been affected in any way by the massive arsenotherapy. Both cases are still in the process of follow-up.
The remaining two patients (Case 1-B. B. and Case 3-I. R.) became pregnant 8 and 14 weeks, respectively, after treatment, at which times their serologies were still positive. These 2 patients received no further antisyphilitic therapy and both were delivered of normal, full-term infants. The child of Case 1-B. B. has been closely followed for 24 weeks and no serological, roentgenographic, or clinical evidence of syphilis has developed. The child of Case 3-I. R. has been followed in a similar fashion for 26 weeks with no apparent signs of syphilis developing. Patients treated with massive arsenotherapy do not have to return week after week for a year and a half, omitting meals before or after therapy to prevent gastro-intestinal symptoms. They return at various intervals only for examination of serology and at times for physical examination. They are admitted to the hospital for a week or a week and a half, as with any other type of infectious disease, and when released from isolation they are, in all probability, incapable of transmitting syphilis to others. Concerning specific therapeutic results to the patients themselves, results would appear to be satisfactory, at least in regard to serology. In our group of 12 patients followed for 24 weeks or longer, 3 have been classed as treatment failures, although close inspection of the case records suggests that in one instance the serology may still revert to negative and in another instance the possibility of reinfec-tion must be considered, thus leaving only one definite case of seroresistance, a condition which sometimes follows the best available treatment.
On the other hand, at present the toxic manifestations of massive arsenotherapy preclude its general use except in a well-organized hospital where capable personnel are always available. The reactions at times are exceedingly trying, witness Case 35, A. Fr. Fortunately, and at least up to this time, we have seen no manifestations of cerebral irritation. This grave complication has been called hemorrhagic encephalitis, although postmortem examination in these cases which have come to autopsy,' has not revealed the characteristic pathological findings of that neurological disease.
The observations of Hyman and his co-workers, together with our limited studies, certainly demonstrate the low incidence of syphilis of the central nervous system following this form of therapy.
Although this form of therapy needs further study in view of the toxic manifestations, it would appear probable that its development to date constitutes a notable advance in the field of syphilotherapy. Its field of particular application is clearly indicated in that group of syphilitics who will not or cannot return week after week for a year and a half to receive their injections, because it is especially this group who pass on the disease. Summary 1. Toxicology, clinical observations, and therapeutic results obtained with massive arsenotherapy in the treatment of 33 cases with primary or secondary syphilis by the continuous intravenousdrip method of Hyman are presented.
2. Females, and particularly pregnant patients, may be treated in this manner.
3. The toxic manifestations of massive arsenotherapy, previously described, such as primary and secondary fever, toxicoderma, jaundice, peripheral neuritis, nausea and vomiting, local thrombophlebitis, and leukopenia were encountered. In addition, the development of a late secondary anemia and certain electrocardiographic changes, of a benign and transient nature, in the T waves are described.
4. Nausea and vomiting are more severe and prolonged in the female than in the male.
5. The preliminary administration of a bismuth compound will not prevent the development of a Herxheimer reaction, at least when it is given in the manner described in the text.
6. Limited study of the dark-field examination of primary and secondary lesions suggests that patients are invariably rendered darkfield-negative within 24 hours.
7. Patients who are re-treated with massive arsenotherapy do not necessarily acquire any sensitivity to arsenic during the first course of treatment. Indeed, in the case of 3 patients who were re-treated, toxic reactions seen during the first course of treatment did not necessarily occur with the second course.
8. The rate of return to sero-negative and the number of patients who attained this status are described.
9. The effect of massive arsenotherapy upon the cerebrospinal fluid is noted. In 2 instances wherein positive serological findings were present at the time of treatment, these abnormalities returned to normal during the follow-up period.
10. In the case of 2 patients who became pregnant within a four-month period following treatment, no further antisyphilitic treatment was given. Despite this, both were delivered of normal full-term infants.
